While No­var­tis ban­ish­es Zol­gens­ma scan­dal scars — Bio­gen goes on a Spin­raza 'of­fen­sive'

While No­var­tis painstak­ing­ly works to mop up the stench of the da­ta ma­nip­u­la­tion scan­dal as­so­ci­at­ed with its ex­pen­sive gene ther­a­py for spinal mus­cu­lar at­ro­phy (SMA) Zol­gens­ma— ri­val Bio­gen is at­tempt­ing to ex­pand the use of its SMA ther­a­py, Spin­raza. 

The US drug­mak­er $BI­IB se­cured US ap­proval for Spin­raza for use in the of­ten fa­tal ge­net­ic dis­ease in 2016. The ap­proval cov­ered a broad range of pa­tients with in­fan­tile-on­set (most like­ly to de­vel­op Type 1) SMA. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.